{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=4",
    "query": {
      "condition": "Resolution",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1356,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T13:46:10.835Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02555306",
      "title": "A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "2.0 mg of DE-122",
          "type": "DRUG"
        },
        {
          "name": "4.0 mg of DE-122",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-16",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 5,
      "location_summary": "Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Michigan"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02555306"
    },
    {
      "nct_id": "NCT01283152",
      "title": "Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Cirrhosis",
        "Portosystemic Encephalopathy",
        "PSE"
      ],
      "interventions": [
        {
          "name": "Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283152"
    },
    {
      "nct_id": "NCT07560735",
      "title": "Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Lifitegrast Ophthalmic Solution 5.0% (Xiidra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toyos Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07560735"
    },
    {
      "nct_id": "NCT03193216",
      "title": "The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Barretts Esophagus With Dysplasia"
      ],
      "interventions": [
        {
          "name": "Alginates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-08-25",
      "completion_date": "2022-01-01",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03193216"
    },
    {
      "nct_id": "NCT03032809",
      "title": "Magnetic Resonance Imaging of Intracranial Vasculopathies",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "CNS Vasculitis"
      ],
      "interventions": [
        {
          "name": "Vessel Wall MR imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-09",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2018-09-17",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03032809"
    },
    {
      "nct_id": "NCT02808143",
      "title": "Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Bladder Carcinoma",
        "Stage 0a Bladder Urothelial Carcinoma",
        "Stage 0is Bladder Urothelial Carcinoma",
        "Stage I Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BCG Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-02-10",
      "completion_date": "2022-08-05",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808143"
    },
    {
      "nct_id": "NCT01869725",
      "title": "Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Medulloblastoma",
        "Childhood Medulloblastoma",
        "Neuroblastoma",
        "Neuroendocrine Tumor",
        "Somatostatinoma"
      ],
      "interventions": [
        {
          "name": "gallium Ga 68-edotreotide",
          "type": "DRUG"
        },
        {
          "name": "positron emission tomography/computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "indium In 111 pentetreotide",
          "type": "RADIATION"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Sue O'Dorisio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2013-04-01",
      "completion_date": "2018-12-26",
      "has_results": true,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01869725"
    },
    {
      "nct_id": "NCT06314893",
      "title": "Establishing a Correlation Between HRM and UGI MM Studies",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophageal Motility Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lexington Health Incorporated",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2022-08-24",
      "completion_date": "2025-01-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "West Columbia, South Carolina",
      "locations": [
        {
          "city": "West Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06314893"
    },
    {
      "nct_id": "NCT00643214",
      "title": "Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tetrix",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Coria Laboratories, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-10",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2008-05-22",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00643214"
    },
    {
      "nct_id": "NCT00221039",
      "title": "Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cutaneous T Cell Lymphoma",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Methoxsalen+ECP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2004-04-02",
      "completion_date": "2011-04-05",
      "has_results": false,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-27T13:46:10.835Z",
      "location_count": 7,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00221039"
    }
  ]
}